--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene ...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and ...
Welcome to the AMD Clinical Case Review, a series of case presentations in the field of age-related macular degeneration. In this video, Jay Chhablani, MD, director of clinical research at the UPMC ...
Michelle L. Thompson, DO, presents the baseline characteristics of the case. Editor's note: The following is an automatically generated transcript of the above video. "50-year-old female patient with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback